The move shows that the board believes that the company’s stock is undervalued, but is likely to sway few who have lately punished the stock over concerns about St. Jude’s Durata ICD lead.
Between Oct. 1 and Nov. 29, the stock has fallen 20.2 percent to $33.69.
“This decision is clearly intended to communicate management’s confidence in light of the recent stock decline, but this statement alone may not be sufficient to ease accelerating concerns on Durata,” said David Lewis, a Morgan Stanley analyst in a research note Friday.
Durata of course has been in the spotlight ever since a previous generation ICD lead was pulled from the market. Analysts have differed over how much risk the Durata poses for the Minnesota medical device maker. But the differing opinions were largely overshadowed when the U.S. Food and Drug Administration issued a less-redacted inspection report than the one St. Jude disclosed that raised serious concerns over how St. Jude does design validation for the Durata.
That caused a deep sell-off.
Now the question is whether Durata will be pulled from the market. Citi analyst Matthew Dodds believes there is a high chance of that happening by mid-2013.
[Photo Credit: Unhappy Trader from Big Stock Photo]